Phase I clinical study (NCT03855371), a combination of decitabine and ATO to treat AML/MDS expressing a classified type of mutant p53, evaluates the side effect and treatment potential of DAC + ATO in TP53 mutated high-risk MDS patients. The gene discussed is TP53; the disease is acute myeloid leukemia.